tbuckley/cabot-search huggingface dataset:
PTH-138 Screening Diabetic Patients for Liver Fibrosis in a Primary Care Diabetes Clinic
Authors: B Deans, F Crimmons, D Al Dulaimi, P Clamp
Journal: Gut (2016)

<h3>Introduction</h3> Patients attending for routine review at a primary care diabetes clinic were screened for advanced fibrosis using a NAFLD fibrosis score calculator. <h3>Methods</h3> The NAFLD Fibrosis Score online calculator (http://nafldscore.com/) has been developed to identify patients that are at significant risk of having advanced fibrosis using body mass index, serum ALT, AST, platelet count, diagnosis of diabetes and age as parameters.<sup>1</sup> We prospectively screened consecutive patients attending for routine review at a primary care diabetes clinic between June and December 2015. Advanced fibrosis was predicted using high cut-off score (&gt;0.676; with previously validated Positive Predictive Value 90%) or excluded for low cut-off score (&lt;−1.455; Negative Predictive Value 93%). Patients with Type 1 and Type 2 diabetes were included. Statistical analysis was performed with Pearson’s and Chi Squared test. <h3>Results</h3> 208 patients were screened, 126 males and 82 females, with a median age of 66 years (range 22–93 years). 21% of patients (29 male and 17 female) with a median age of 76, had a NAFLD Fibrosis score predicting a significant risk of advanced fibrosis and identifying them as appropriate for referral to secondary care. A NAFLD score predicting a significant risk of advanced fibrosis increased with age: 5.6% (1/ 18) of patients aged less than 50, 9.5% (4/42) of patients aged 50–59 years, 12.5% (7/56) of patients aged 60–69, 35.1% (20/57) aged 70–79 and 56% (14/25) of patients aged 80 years and older. Advanced fibrosis was predicted for 23% male (29/126) and 21% females (17/82) patients. Advanced fibrosis was excluded in 13.5% patients (28/208). As expected, there was a moderate positive correlation between NAFLD score and age (r = 0.56). There was no significant difference in the proportion of male or female patients with advanced fibrosis (p = 0.7). <h3>Conclusion</h3> It is practical to routinely screen patients for liver fibrosis secondary to NAFLD within a primary care diabetes clinic using the NAFLD fibrosis score calculator and identify a significant proportion of patients at significant risk of advanced fibrosis. <h3>Reference</h3> 1 Angulo P, Hui JM, Marchesini G, <i>et al</i>. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. <i>Hepatology</i> 2007;<b>45</b>(4):846-854 <h3>Disclosure of Interest</h3> None Declared
Use of Plerixafor in Predicted and Proven Poor Mobilizer (according to GITMO criteria). Experience of Policlinico Universitario Tor Vergata
Authors: Massimiliano Postorino, Alessandro Lanti, Eleonora Fiorelli, Angelo Salvatore Ferraro, Oana Marilena Chiru, Raffaella Massarelli, Luca Franceschini, Giorgia Guiducci, Ida Provenzano, Livio Pupo, Anna Giulia Zizzari, Gaspare Adorno, Maria Cantonetti, Giancarlo Isacchi, Sergio Amadori
Journal: Blood (2012)
THU0041 Large Country Differences in Work Outcomes in Patients with RA – An Analysis in The Multinational Study Comora
Authors: A. Van Der Zee-Neuen, P. Putrik, S. Ramiro, A. Keszei, I. Hmamouchi, M. Dougados, A. Boonen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Better insight into country- or system related differences in work outcomes is important when trying to take country specific measures aiming to improve short- and long-term work outcomes of patients with rheumatoid arthritis (RA). <h3>Objectives</h3> We aimed to explore whether country of residence and specific country characteristics are associated with work outcomes in patients with RA. <h3>Methods</h3> Data from the cross-sectional multinational study COMORA (17 countries) were used. Work outcomes were measured by the Work Productivity and Activity Impairment Questionnaire (WPAI) assessing employment (yes/no), absenteeism (% of time) and presenteeism (% of normal productivity). The contribution of country of residence, gross domestic product (GDP), human development index (HDI), unemployment rate, social protection expenditures (SPE) and world region to the work outcomes was investigated in logistic or ordinal logistic regression models after adjusting for clinical and sociodemographic factors. <h3>Results</h3> The study sample consisted of 3,920 patients of whom the mean age was 56 (SD 13), 3,191 (82%) were female and 1,197 (31%) were employed. Large country differences were found for all work outcomes. The country with the best work outcome was used as reference. Morocco showed the lowest adjusted employment compared to the USA (OR 0.17; [95%CI 0.10; 0.30]) followed by Egypt (OR 0.37 [95% CI 0.24; 0.56]), Korea (OR 0.45 [95% CI 0.31; 0.65]), Venezuela (OR 0.53 [95% CI 0.34; 0.84]), Taiwan (OR 0.54 [95% CI 0.36; 0.80] and France (OR 0.66 [95% CI 0.46; 0.95]) (figure 1). Compared to Japan, absenteeism was highest in Morocco (OR 12.63 [4.45; 35.89]) followed by Hungary (OR 6.49 [95%CI 2.45; 17.23]) and Argentina (OR 3.25 [95%CI 1.25; 8.45]). Compared to Venezuela, presenteeism was highest in Taiwan (OR 13.81 [5.95; 32.04]) followed by Korea (OR 10.59 [95%CI 4.77; 25.13]) and Italy (OR 8.96 [95%CI 3.53; 22.76]). All country indices except SPE were significantly associated with the outcomes. Low GDP countries had lower odds of employment (OR 0.66; [0.54; 0.80]), higher odds of absenteeism (OR 2.68 [1.91; 3.76]), but a lower odds of presenteeism (OR 0.45 [0.32; 0.62]) compared to high GDP countries. <h3>Conclusions</h3> Substantial differences in work outcomes among RA patients were observed between countries. Lower economic and human welfare were associated with worse employment, higher absenteeism but paradoxically also with lower presenteeism. <h3>Disclosure of Interest</h3> None declared
Impact of HLA Allele Mismatch on the Outcome of Patients with Reduced-Intensity Allogeneic Haematopoietic Stem Cell Transplantation from Unrelated Donors: Analysis of 103 Patients of the French Registry.
Authors: Andrea Toma, Marie-Lorraine Balere-Appert, Zina Chir, Jean-Michel Boiron, Pierre Bordigoni, Gerard Socie, Jean-Paul Vernant, Marc Renaud, Noel-Jean Milpied, Mauricette Michallet, Eric Deconninck, Denis Guyotat, Frederic Garban, Anne Sirvent, Nathalie Contentin, Didier Blaise, Colette Raffoux, Agnes Buzyn
Journal: Blood (2006)
Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study
Authors: Karin Fjordén, Frida Pauly, Sirpa Leppä, Harald Holte, Magnus Björkholm, Oystein Fluge, Lars Möller Pedersen, Mikael Eriksson, Anna Isinger-Ekstrand, Carl Borrebaeck, Mats Jerkeman, Christer Wingren
Journal: Blood (2014)
Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Novel Genetic Subtypes.
Authors: Sami N. Malek, Lisa A. Kujawski, Harry P. Erba, Mark S. Kaminski, Andrzej Jakubowiak, Amanda Dressel, Chris M. Saddler, Kerby A. Shedden, Peter D. Ouillette
Journal: Blood (2006)
Randomized Phase II Trial Comparing Cyclosporine (CSP) and Tacrolimus (TAC) for Methotrexate (MTX)-Free Graft-Versus-Host Disease (GVHD) Prophylaxis after Allogeneic Transplantation from a Matched Related Donor (MRD) with a Reduced-Intensity Regimen Containing Cladribine and Busulfan
Authors: Sung-Won Kim, Takahiro Fukuda, Shotaro Hagiwara, Tsunehiko Komatsu, Tetsuya Goto, Yasunori Ueda, Toshiro Ito, Masayuki Hino, Kazutaka Sunami, Ryuji Tanosaki, Shin-ichiro Mori, Masahiro Kami, Kinuko Tajima, Yoichi Takaue
Journal: Blood (2008)
Preclinical Applications of 3'-Deoxy-3'-[<sup>18</sup>F] Fluoro-thymidine in Oncology - A Systematic Review
Authors: Sonja Schelhaas, Kathrin Heinzmann, Vikram R Bollineni, Gerbrand M Kramer, Yan Liu, John C Waterton, Eric O Aboagye, Anthony F Shields, Dmitry Soloviev, Andreas H Jacobs
Journal: Theranostics (2016)

The positron emission tomography (PET) tracer 3'-deoxy-3'-[
FRI0532 Association between The 7-Joint Ultrasound Score (US7S) and Physical Function in Rheumatoid Arthritis: Table 1.
Authors: J. Zavada, P. Hanova, J. Hurnakova, M. Uher, L. Puczokova, S. Forejtova, M. Klein, H. Mann, M. Olejarova, O. Sleglova, K. Pavelka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To investigate the longitudinal relationship between physical disability and US7S in a prospective cohort of patients with RA. <h3>Methods</h3> A cohort of 205 RA pts (49 incident/156 prevalent) (mean±SD age 55±14 years, 47% RF+, 63% ACPA+, DAS28-CRP 3.7±1.5, mHAQ 0.43±0.52, disease duration in incident vs. prevalent pts. 0.9±0.7 vs. 8.1± 8.3 resp.) was followed up longitudinally for 29±9 months. Assessments at baseline and at month 3 and 6, and then every 6 months comprised DAS28-CRP, functional evaluations using the modified Health Assessment Questionnaire (mHAQ) and an ultrasound assessment of the clinically dominant hand and foot by US7S<sup>1</sup>. US7S consists of 5 subscores for synovitis (syn) and tenosynovitis (ten) assessed by grey-scale (GS) and Power-Doppler (PD), and an erosions score (ES). A linear mixed model was used to assess the longitudinal relationship between US7 subscores and mHAQ. Univariate analyses with an interaction term for incident vs. prevalent disease, and a multivariate analysis (with age, sex, BMI, RF and ACPA status, and DAS28-CRP entered as covariates) were performed. <h3>Results</h3> In univariate analyses (table) mHAQ was longitudinally associated with GSsyn, PDsyn, PDten and GSten US7 subscores (with resp. β coefficients significantly higher in incident patients), while erosions score was a significant predictor of mHAQ only in prevalent pts. In a multivariate model the US7 subscores were individually no longer significant predictors of mHAQ, although the R<sup>2</sup> of the model was improved by addition of US7 items from 43.6 to 46.9 (p&lt;0.001 for improvement of R<sup>2</sup>). <h3>Conclusions</h3> This study provides evidence that RA related activity and damage reflected by US7S contribute to impaired physical function in RA, and their impact differs in early and established disease. When combined with conventional clinical parameters, the additional explanatory value of US7 for mHAQ was only minor. <h3>References</h3> Backhaus M. et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum. 2009 Sep 15;61(9):1194–201 <h3>Acknowledgement</h3> This work was supported by the project (Ministry of Health, Czech Republic) for consensual development of research organization 023728, and IGA grant NT12437 <h3>Disclosure of Interest</h3> None declared
Direct Healthcare Costs of Treated Multiple Myeloma: Results from a Population-Based Study
Authors: Alessandro Corso, Enrica Morra, Paolo Corradini, Monica Galli, Anna Maria Cafro, Roberta Ciampichini, Paolo Cozzolino, Virginio Chiodini, Claudia Crippa, Giuseppe Rossi, Giancarlo Cesana, Lorenzo Giovanni Mantovani
Journal: Blood (2014)
Analysis of 608 Umbilical Cord Blood (UCB) Transplants: HLA-Match Is a Critical Determinant of Transplant-Related Mortality (TRM) in the Post-Engraftment Period Even in the Absence of Acute Graft-vs-Host Disease (aGVHD).
Authors: Juliet N. Barker, Andromachi Scaradavou, Cladd E. Stevens, Pablo Rubinstein
Journal: Blood (2005)
PTU-062 Vedolizumab: Early Experience and Medium-Term Follow up Data from Two UK Tertiary IBD Centres
Authors: MA Samaan, P Pavlidis, E Johnston, B Warner, J Digby-Bell, I Koumoutsos, S Fong, R Goldberg, S Gulati, L Medcalf, M Sastrillo, T Bedwell, C Brown-Clarke, J Bidwell-Sullivan, K Forsyth, E Lee, A Stanton, J Duncan, G Chung-Faye, P Dubois, N Powell, S Anderson, J Sanderson, B Hayee, P Irving
Journal: Gut (2016)

<h3>Introduction</h3> Vedolizumab was recently granted NICE approval for moderate-to-severe Crohn’s disease (CD) and ulcerative colitis (UC). Novel pathways agreed by our CCG meant that patients at Guy’s &amp; St. Thomas’ and King’s College Hospitals had early access to vedolizumab. <h3>Methods</h3> Records of patients commencing vedolizumab between Nov 2014–15 were screened. Those completing at least 14 weeks of treatment were included. Clinical activity was assessed using Harvey-Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI) at baseline, 14 and 30 weeks. Response: HBI/SCCAI reduction ≥3. Remission: HBI &lt; 5 or SCCAI &lt;3. Continuous data are summarised as medians (range). Pre- and post-induction values were compared using Wilcoxon signed-rank test. <h3>Results</h3> 60 patients (CD: 32, 53%, UC 25, 42%, IBD-U 3, 5%) commenced vedolizumab (m:f 29:31, age: 39 (18–74), follow-up: 5 months (1–13)). 19 were excluded from our analysis (3 IBD-U, 5 stomas, 11 treated for &lt;14 weeks). Clinical data from the remaining 41 was analysed. Of 32 patients with active disease at baseline, 17 (53%) responded and 11 (34%) achieved remission by week 14. The response and remission rates for CD were 8/15 (53%) and 6/15 (40%). In UC they were 9/17 (53%) and 5/17 (29%). Response and remission rates in anti-TNF experienced patients were 12/26 (46%) and 6/36 (35%) compared to 5/6 (83%) and 5/6 (83%) in anti-TNF naïve patients, respectively. 7/11 (64%) with active disease at baseline who completed 30 weeks of treatment responded and achieved remission. Faecal calprotectin fell significantly (pre-induction: 1076 (90–4800), post-induction: 478 (10–3184), p = 0.029 for n = 14) and CRP remained stable (pre-induction: 4 (1–70), post-induction: 4 (1–72), p = 0.28 for n = 40). Rates of steroid use at each time point: 19/41 (46%) at baseline, 11/41 (21%) at week 14 and 3/15 (20%) at week 30. Surgery was required in 4/41 (10%, CD:3 and UC:1). <h3>Conclusion</h3> Our experience mirrors a previously reported real-world cohort<sup>1</sup> and demonstrates similar efficacy to the GEMINI trials. This data demonstrates a meaningful reduction in clinical and biochemical disease activity as well as a steroid-sparing effect in patients with complex and previously refractory disease. We did not see a significant difference in efficacy between patients with UC and CD. <h3>Reference</h3> 1 Christensen B. <i>et al</i>. <i>Post-marketing experience of vedolizumab for IBD: The University of Chicago experience</i>. ECCO; Barcelona, 2015. <h3>Disclosure of Interest</h3> None Declared
Endovascular Treatment for Patients With Acute Stroke Who Have a Large Ischemic Core and Large Mismatch Imaging Profile
Authors: Leticia C. Rebello, Mehdi Bouslama, Diogo C. Haussen, Seena Dehkharghani, Jonathan A. Grossberg, Samir Belagaje, Michael R. Frankel, Raul G. Nogueira
Journal: JAMA Neurology (2016)

Endovascular therapy (ET) is typically not considered for patients with large baseline ischemic cores (irreversibly injured tissue). Computed tomographic perfusion (CTP) imaging may identify a subset of patients with large ischemic cores who remain at risk for significant infarct expansion and thus could still benefit from reperfusion to reduce their degree of disability.To compare the outcomes of patients with large baseline ischemic cores on CTP undergoing ET with the outcomes of matched controls who had medical care alone.A matched case-control study of patients with proximal occlusion after stroke (intracranial internal carotid artery and/or middle cerebral artery M1 and/or M2) on computed tomographic angiography and baseline ischemic core greater than 50 mL on CTP at a tertiary care center from May 1, 2011, through October 31, 2015. Patients receiving ET and controls receiving medical treatment alone were matched for age, baseline ischemic core volume on CTP, and glucose levels. Baseline characteristics and outcomes were compared.The primary outcome measure was the shift in the degree of disability among the treatment and control groups as measured by the modified Rankin Scale (mRS) (with scores ranging from 0 [fully independent] to 6 [dead]) at 90 days.Fifty-six patients were matched across 2 equally distributed groups (mean [SD] age, 62.25 [13.92] years for cases and 58.32 [14.79] years for controls; male, 13 cases [46%] and 14 controls [50%]). Endovascular therapy was significantly associated with a favorable shift in the overall distribution of 90-day mRS scores (odds ratio, 2.56; 95% CI, 2.50-8.47; P = .04), higher rates of independent outcomes (90-day mRS scores of 0-2, 25% vs 0%; P = .04), and smaller final infarct volumes (mean [SD], 87 [77] vs 242 [120] mL; P < .001). One control (4%) and 2 treatment patients (7%) developed a parenchymal hematoma type 2 (P > .99). The rates of hemicraniectomy (2 [7%] vs 6 [21%]; P = .10) and 90-day mortality (7 [29%] vs 11 [48%]; P = .75) were numerically lower in the intervention arm. Sensitivity analysis for patients with a baseline ischemic core greater than 70 mL (12 pairs) revealed a significant reduction in final infarct volumes (mean [SD], 110 [65] vs 319 [147] mL; P < .001) but only a nonsignificant improvement in the overall distribution of mRS scores favoring the treatment group (P = .18). All 11 patients older than 75 years had poor outcomes (mRS score >3) at 90 days.In properly selected patients, ET appears to benefit patients with large core and large mismatch profiles. Future prospective studies are warranted.
Immunoglobulin Gene Translocations Are Frequent in Unclassifiable CD5+ Small B-Cell Leukemias and in Particular, a Novel Subtype Characterised by t(14;19)(q32;q13) and Deregulation of BCL3 Is Described.
Authors: Alison Morilla, Paloma Martin, Toon Min, Ricardo Morilla, Ellen Remstein, David Gonzalez, Claire Dearden, Gareth J. Morgan, Estella Matutes
Journal: Blood (2007)
Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome
Authors: Guillermo Sanz, Benet Nomdedeu, Esperanza Such, Teresa Bernal, Mohamed Belkaid, Ma Teresa Ardanaz, Victor Marco, Carme Pedro, Fernando Ramos, Maria Consuelo del Cañizo, Elisa Luño, Francesc Cobo, Felix Carbonell, Valle Gomez, Juan A Muñoz, Mari Luz Amigo, Alicia Bailen, Santiago Bonanad, Mar Tormo, Rafael Andreu, Beatriz Arrizabalaga, Maria J. Arilla, Javier Bueno, Maria J. Requena, Joan Bargay, Joaquin Sanchez, Leonor Senent, Leonor Arenillas, Raquel de Paz, Blanca Xicoy, Rafael Duarte, Jose Cervera
Journal: Blood (2008)
AB1058 The New Joint Weighted Scoring System Which Predicts The Modified Health Assessment Questionnaires Scores in Rheumatoid Arthritis Patients: A Validation Study Using The National Database of Rheumatic Diseases by iR-net in Japan
Authors: K. Ono, S. Ohashi, H. Oka, Y. Kadono, Y. Omata, T. Matsumoto, N. Izawa, J. Nishino, S. Tanaka, S. Tohma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> We reported the impact of each joint disease on the MHAQ (Modified Health Questionnaire) by using 2011 NinJa (the National Database of Rheumatic Diseases by iR-net in Japan) data in the past study. The odds ratio of physical impairment according to the MHAQ using multivariable logistic regression models for bilateral and unilateral joints, respectively, were: shoulder, 4.0 and 1.8; elbow, 2.6 and 1.8; wrist, 1.9 and 1.5; hip, 1.7 and 3.0; knee, 2.6 and 1.9; ankle, 2.3 and 2.0; finger, 1.4 and 1.2; and toe, 1.0 and 1.1. The MHAQ score was significantly affected by shoulder, elbow, wrist, knee, and ankle joint disease, and bilateral disease tended to have a greater effect on physical impairment than unilateral disease. We also developed a joint weighted scoring system from the results of the odds ratio. An integer score was assigned to each identified bilateral and unilateral joint disease, respectively, as follows: shoulder, 4 and 2; elbow, 3 and 2; wrist, 2 and 2; hip, 0 and 3; knee, 3 and 2; ankle, 2 and 2; finger, 1 and 1. We acquired 3 points as the cut-off value of this scoring system through statistical analysis (Modern Rheumatology, 2015, Epub ahead of print). <h3>Objectives</h3> To validate this scoring system by applying to NinJa in 2014. <h3>Methods</h3> A total of 13,459 subjects (2,586 men, 10,873 female) from NinJa in 2014 were analyzed. The presence or absence of disease in each joint (swelling and/or tenderness were considered as disease) and whether the disease was unilateral or bilateral were investigated. ROC curve analysis was performed to each patient with total score calculated according to the scoring system. <h3>Results</h3> The patients9 mean age and disease duration was 64.1 and 13.0 years, respectively. The Disease Activity Score-28CRP was 2.4. ROC analysis9 results were as follows: cut-off value, 3 points; AUC, 0.68; sensitivity, 53.4%; and specificity, 75.0%. <h3>Conclusions</h3> This joint weighted scoring system was validated and suggested to be useful to predict of functional disability of RA patients in a daily practice. <h3>Disclosure of Interest</h3> None declared
FRI0220 Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in A Real Life Setting: The Act-Solo Study 12 Months Results
Authors: J. Tebib, I. Idier, M. Coudert, J.-F. Maillefert, R.-M. Flipo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although the use of a biologic as monotherapy is not the standard in Rheumatoid Arthritis (RA), it concerns around a third of the patients. The objectives of the Act Solo study was to evaluate tocilizumab (TCZ) alone (Mono) or in combination (Combo) at 12 months in real life. <h3>Methods</h3> Prospective, multicenter, longitudinal, non-interventional 12-month study in RA pts requiring TCZ according to their physician. Besides drug retention rate, efficacy and safety, the effect of Mono when compared to Combo was evaluated using a propensity score. Efficacy population was pts fulfilling inclusion and non-inclusion criteria and with ≥1 TCZ infusion. Safety population was all pts with ≥1 TCZ infusion. <h3>Results</h3> 608 pts were recruited of whom 603 were analysed for safety and 577 (Total) for other endpoints. At baseline: mean age 57±13 years, 454 (79%) females, at least 1 co-morbidity: 409 (71%), mean RA duration 11±9 years, RF or ACPA positive: 478 (86%), erosive disease: 435 (77%), mean DAS28 5.2±1.3. Past RA treatments included DMARDs + biologics in 75%, only DMARDs in 24%. MTX was previously prescribed in 95% of pts and in 71% within the last 2 years. TCZ Mono was initiated in 228 (40%) pts and TCZ Combo in 349 (60%) pts of whom 80% received MTX (mean 16±5mg/w). Steroids (GCs) were used in 386 (67%) pts (mean 10±7mg/d). 337 pts completed M12 visit. 194 pts withdrew for: AE 53 pts, inefficacy 88, patients wish 12, lost to follow-up 23, other 18. At M12, drug retention rate was 69% in Total, 67% in Mono, 71% in Combo (Fig.). Mean number of TCZ infusions was 9.4±4.1; mean time between infusions was 31.8 ±12.6 days. 29% of the pts experienced at least 1 discontinuation, 25% and 33% in Mono and Combo groups respectively. DMARD was added in 20 Mono and definitely stopped in 25 Combo pts. 170 (50%) pts remained on GCs, 66 (51%) in Mono group and 104 (50%) in Combo group. At M12, mean DAS28 in Total, Mono and Combo were 2.4±1.3, 2.4±1.3 and 2.3±1.2 respectively. DAS28 remission was 35% in Total, 35% and 36% in Mono and Combo respectively (p=0.83). Using the propensity score, no effect of Mono was observed on drug retention HR=1.194 [0.852,1.673], p=0.30; DAS remission OR=1.111 [0.773,1.597], p=0.57; or GCs use OR=0.880 [0.558,1.387], p=0.58 at M12. No new safety signal was reported. 325 (54%) patients had at least one AE, 74 (12%) had at least one serious AE with no differences between Mono and Combo. <h3>Conclusions</h3> The Act Solo study confirms, in real life, the clinical results of RCTs showing a comparable efficacy of TCZ as monotherapy when compared to combotherapy. No new safety signal occurred. <h3>Disclosure of Interest</h3> J. Tebib: None declared, I. Idier Employee of: Chugai Pharma France, M. Coudert: None declared, J.-F. Maillefert: None declared, R.-M. Flipo Consultant for: Roche SAS and Chugai Pharma France